The Quantel Medical Company

About us

Quantel Medical

is part of the Quantel group
Laser Plant Electronic

Quantel Group

A french group specialised in
laser technology since 1970

Created in 1970

Global position in solid lasers

Scientific lasers

Industrial lasers

Medical lasers

Quoted company

INDUSTRIAL AND SCIENTIFIC LASERS

MILITARY AND SPATIAL DEVELOPMENT CONTRACTS

LASER DAMAGE TESTING

MEDICAL SYSTEMS FOR OPHTHALMOLOGY

Nanosecond Q-switched Nd:YAG lasers, fiber lasers, laser diodes / semi-conductor products for PIV, LIBS, flat panel diplay repair, LIDAR, atom cooling or marking applications.

International development contracts for aerospace, space or defense, design and development of lasers for national and global projects, for industrial companies in France or in the USA.

Full range of laser exposure testing services: damage threshold, durability certification, optical density, specialty testing and other exposure test services available at key laser wavelengths.

Ophthalmic lasers to treat retinal diseases, secondary cataract, glaucoma and ARMD; Ultrasound Systems for ocular measurements and diagnosis; lines of consumable: Laser Probes and Single Use Lenses.

Electronic Space Laser tests Eye Laser blank
Electronic Space Laser tests Eye

Echography and laser

40 years of
Research and development
Woman Chip Laser

Quantel Medical

Global therapeutic solutions in ophthalmology

The Quantel Group from France founded Quantel Medical in 1993. It was formed as a subsidiary to offer innovative solutions in ophthalmology, from ocular diagnosis to laser treatment. Quantel Medical is headquartered in Cournon d’Auvergne on the outskirts of Clermont-Ferrand, a region known for technologically advanced companies.

The company manufactures and markets a full range of ultrasound and laser products designed for ophthalmology. Being a pioneer in the development of medical technologies, Quantel Medical has become the leader in both ocular ultrasound and laser photocoagulation.

 

 

 
 

History

Left

1970

Background
Quantel Group is founded

Quantel Group is founded, specializing in solid-state lasers for Medical and Industrial/Scientific applications, currently based in Paris, France.

1981

Background
Big Sky Laser is founded

Big Sky Laser is founded and acquires and merges leading laser development companies, resulting in Quantel USA.

1993

Background
Quantel Medical is founded

Quantel created a subsidiary with the acquisition of Biovision, later becoming Quantel Medical.
This merge combined Quantel’s long history of laser expertise with ophthalmic industry experts, resulting in the two ophthalmic product lines: lasers and ultrasound.

1994

Background
Quantel Medical develops 2 worldwide innovations

Quantel Medical begins development of the world’s first solid-state 532nm photocoagulator with a diode pump - a world-class innovation.
Introduction of parfocal zoom on a slit-lamp adapter.

1995

Background
Viridis™ introduction

Quantel Medical introduces the Viridis™ solid-state photocoagulator, bringing the era of argon lasers in ophthalmology to an end.

1996

Background
Quantel Medical's global growth

Quantel Medical’s international business grows to more than 70 distributors worldwide.
A direct office in Asia is established.

1997

Background
Quantel Group listed on the New Paris Stock Exchange

Quantel Group is listed on the New Paris Stock Exchange and new capital is secured to expand the business.
Quantel introduces the Viridis Twin offering 532nm and 810nm in one system.

1999

Background
Quantel creates a USA subsidiary, Quantel Medical, Inc.

Introduction of Activis™ and Iridis™ for treating ARMD and the Optimis™ Yag for laser capsulotomy.
Quantel enters partnership with Coherent to OEM the Novus Verdi, selling over 1000 systems in the next five years.

2000

Background
Pocket™

Pocket™ receives FDA clearance.

2001

Background
Four major products

Quantel Medical advances the ultrasound market with two new products: Cinescan™ A/B and the Axis II™ biometer.
Two first to market ultrasound features are introduced: Varigain™ and Cineloop™.

2002

Background
Introduction of the Compact™, a new A/B-scan ultrasound platform

Iridis receives FDA clearance.
Cinescan receives FDA clearance.

2003

Background
A first in the world of diagnostic ultrasound

2 high-frequency probes are introduced for the retina and the anterior chamber.
Introduction of the Pocket II™ pachymeter for glaucoma diagnosis.
Viridis Twin receives FDA clearance.

 

2004

Background
Quantel Medical celebrates its 10th anniversary

In 10 years, 8,000 ultrasound systems and 2,500 lasers are installed.

2005

Background
Introduction of new technologies

Introduction of Vitra™ – the smallest 532nm photocoagulator in the ophthalmic market, FDA clearance received.
Introduction of Aviso™,  a new generation of ultrasound on a PC platform, FDA clearance received.
Optimis receives FDA clearance.

2007

Background
Supra™, the new photocoagulator laser

Quantel Medical introduces multi-color and micropulse features with the Supra™ photocoagulator. The first time MicroPulse® is offered in multiple wavelengths: 532nm and 660 or 810nm, FDA clearance received.
A true yellow laser, Supra 577.Y, is introduced as the benchmark product to treat near the macula.

2008

Background
Introduction of 7 new products and features

Solutis™, an SLT laser for glaucoma treatments is introduced.
Echo Data manager is introduced: to meet DICOM and EMR standards.
Lin25 and Lin50 are introduced: linear-scanning UBM probes designed for for the anterior chamber.
ProBeam™ is introduced: a biometry probe with a built-in laser pointer for high-precision measurements.
Axis Touch™ and Compact Touch™ are introduced: A new generation of ultrasound systems with touch-screen control.

2009

Background
Quantel Medical introduces the world’s first 577nm multispot pattern scanning laser

Quantel Medical introduces the world’s first 577nm multispot pattern scanning laser with MicroPulse®: SupraScan™ 577. FDA clearance received for the Supra 577.Y.

2010

Background
The ultrasound range is enhanced with the addition of three new products

Aviso S, Axis Nano, and Compact Touch STS.
Supra Scan receives FDA clearance for the 532nm wavelength.

2011

Background
New headquarters offices

Quantel Medical establishes new headquarters in Clermont-Ferrand with increased R&D, Manufacturing and Global Sales management capacity.

2012

Background
Introduction of the Vitra™ Multispot

Introduction of the Vitra™ Multispot, a pattern-scanning photocoagulator specifically designed for PRP treatments.
Supra Scan 577 receives FDA clearance.
Expansion of the U.S. customer support operation bringing increased technical and clinical support to U.S. customer base.

2013

Background
20th Anniversary

VitraTM Multispot receives FDA clearance.
Direct sales operations in France and the U.S. and a network of distributors in over 110 countries result in over 22,000 ultrasound and laser systems installed worldwide. 

2014

Background
Addition of two new disposable products to portfolio

Quantel Medical introduces Optimis Fusion, SLT/YAG laser platform easily combined with VitraTM or VitraTM Mulispot lasers, offering a glaucoma, Cataract and retina laser in one laser. Optimis Fusion receives FDA clearance.
The company also introduces two new disposable product ranges: Vitra™ Probes, premium next generation laser probes for retina treatment, and a new range of Single Use Lenses for the diagnosis and treatment of the eye.

2015

Background
A new generation of 10 MHz B probe

Quantel Medical introduces its new generation of 10 MHz B probe, offering multiple diagnostic advantages and new capabilities. 
This new 10 MHz B probe is compatible with our AvisoTM and Aviso STM systems.

2016

Background
World Premiere With Fiber Laser Technology: New Easyret Photocoagulator

Quantel Medical launches New Easyret fully integrated 577nm Yellow photocoagulator for macular and peripheral retinal pathologies based on fiber laser technology.

Right

17 Innovations in 23 Years


Patients and users protection first


Medical devices market is a tightly regulated sector at both international, European and national levels. Quantel Medical’s Quality Department is in charge of certifying a top quality of services, carefully considering both patients and users protection, and environment issues. All Quantel Medical’s departments are certified to both ISO 9001 and ISO 13485.

 

Learn more about:                 ISO 9001 & ISO 13485

 


Quantel Medical: a high compliance level


Quantel Medical is closely tied to Regulatory Affairs, maintaining a high compliance level through mandatory conformity marking, certifying that its products meet all the requirements in many different countries. This implies to constantly track legal and regulatory developments worldwide, allowing Quantel Medical to register its products with all the technical support and processes required.

Quantel Medical’s products are all complying with CE Mark, enabling the free movement within the European market.


Learn more about:                                     CE MARKING

 


Customer-First Promise


Quantel Medical is committed to providing each customer with comprehensive customer support programs to ensure their success.

From initial installation and training, to service and technical support throughout the life of the device, Quantel will provide solutions to keep your staff trained and your device up and running to avoid any downtime in your practice.

 

Management Team

Jean-Marc Gendre

Jean-Marc Gendre

CEO

8 years of experience at Quantel Medical

With his 25 years of experience, Jean-Marc Gendre‘s renowned expertise in Ophthalmology is not to demonstrate anymore.

Within his strong knowledge in the medical field, he quickly reached a Marketing and Sales Director position at American Medical System. Heading Quantel Medical since 6 years, Jean Marc Gendre gives a steady growth dynamic, enabling the company to strengthen its global leadership position on ophthalmology’s market.

 

Pascal Besson

Pascal Besson

VP Sales

8 years of experience at Quantel Medical

Expert in the development of worldwide ophthalmic commercial activities since 20 years, Pascal Besson has been responsible for French and Belgium Refractive Sales Department at Abbott Medical Optics Inc., between 2002 and 2009.

Since then, he is taking care of Quantel Medical’s sales, evolving from Sales & Service Director EMEA & Latin America to VP Sales with the high responsibility to develop the activity worldwide.

Christian Chabrier

Christian Chabrier

Chief Operating Officer

23 years of experience at Quantel Medical

Entered at the beginning of the Quantel Medical adventure, with a past experience in the same field at Biophysique Medical which has become Alcon, Christian Chabrier holds a position of technical director. He is responsible for the technical operating, namely the Research, the industrialization and the production of Quantel medical goods.

He has become an expert in the field of managing people since 30 years in Biophysique Medical, Alcon, and Quantel Medical, as well as in the technical field of ultrasound and medical lasers, and in a generic manner in the development of new medical devices.

Florence Degoulange

Florence Degoulange

Finance Manager

22 years of experience at Quantel Medical

After having spent, at the beginning of her career, two years within a refrigerating transportation group as a cash manager, she arrived in the Auvergne and integrated BV international (which became Quantel Medical) about almost 20 years ago.

Her position and function have evolved with the structure as the team included less than ten people when she arrived. During 20 years she has contributed to the growing of Quantel Medical through her function as a responsible of the Financial and Management Department.

Jan-Philippe Heydel

Jan-Philippe Heydel

Marketing Director

9 years of experience at Quantel Medical

Over his 20 years of experience in ophthalmology, Jan-Philippe Heydel has served several capital equipment and pharmaceutical companies in different operational roles in export sales and marketing.

He participated in the launching and development of products in various geographical areas: Asia, Middle-East, Africa and South America. He joined Quantel Medical in 2011 as product manager of the ultrasound range. Since the beginning of 2015, he is in charge of Quantel Medical marketing department.

Bruno Pagès

Bruno Pagès

Quality & Regulatory Affairs Director

Few months of experience at Quantel Medical

Bruno started his career as a consultant in quality management. In 2000, he joined EDAP-TMS, a company specialized in urology (prostate cancer and kidney stones) where he was head of department for quality and regulatory affairs. Given the international activities of EDAP-TMS, Bruno has gained a large experience in international environments for both quality and regulatory issues.

He is now at the head of Quantel Medical’s regulatory and quality affairs since September 2016.

 

News

Quantel Medical Receives FDA Approval for Easyret Photocoagulator Laser

Quantel Medical today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on July 25, 2017 for the innovative new Easyret fully integrated 577nm yellow photocoagulator, which is used to treat certain forms of macular edema and peripheral retinal pathologies.

In 1995, Quantel was the first company to introduce solid-state diode-pumped technology for green photocoagulators. In 2016, Quantel introduced a new revolution with fiber laser technology for 577nm yellow lasers in Europe. This technical breakthrough is based on Quantel’s proprietary ELBA fiber laser technology, which the company has utilized in scientific and industrial areas.  We are very excited to bring this technology to ophthalmic surgeons and their patients in the United States in 2017,” said Jean‐Marc Gendre, CEO of Quantel Medical. “The Easyret’s ELBA fiber laser cavity delivers pure 577nm yellow wavelength in a uniform top-hat laser spot profile, making it ideal for ophthalmic applications. The technology is a compact, reliable variation on solid-state lasers that provides an extended lifetime of service. Quantel engineers worked closely with surgeons to design a fully integrated system with an intuitive interface to ensure optimal ergonomics and ease of use. Surgeons’ input was essential to the Easyret’s design, and we are pleased with their enthusiasm for this new technology.”

The Easyret has a broad range of settings for treatment of pathologies such as diabetic retinopathy, macular edema and central serous chorioretinopathy. In addition to SingleSpot treatment mode, surgeons can select Multispot mode for a pattern of simultaneous targets or the SubLiminal™ mode, which enables them to customize a train of short pulses to precisely manage the thermal effect on targeted tissues.

Quantel Medical Launches Breakthrough SubCyclo Laser Procedure for Treatment of Glaucoma

Safe, effective, 2-minute procedure represents important advance in treatment of this progressive, sight-threatening disease.

Glaucoma is a group of eye diseases that develop due to elevated intraocular pressure (IOP), which can affect the optic nerve and cause vision loss. According to the World Health Organization, glaucoma affects more than 65 million people worldwide and is the second leading cause of legal blindness. Thermal transscleral cyclophotocoagulation is an effective treatment for glaucoma that reduces production of aqueous humor in the eye’s ciliary body, lowering IOP. However, because it is a destructive procedure associated with side effects and complications, it is recommended only for patients with refractory glaucoma for whom previous treatments have failed. 

SubCyclo is a novel non-thermal glaucoma treatment based on the transscleral cyclophotocoagulation principle. The procedure lowers IOP by stimulating the ciliary body and the uveoscleral pathway, a route of aqueous outflow, without destructive effects. The SubCyclo probe is available on Quantel’s Supra 810 laser and based on SubLiminal™ proprietary technology.  

“SubCyclo preserves the structures of the ciliary body and improves the uveoscleral outflow. Because it is not destructive, it can be used earlier in the disease process for patients with open-angle and closure-angle glaucoma instead of for only refractory cases, and it is repeatable if needed,” said Dr. Nassima Benhatchi, Hôpital Saint Joseph, Paris, France.  “What’s more, this is a fast, easy procedure that we can perform with local anesthesia in 2 minutes.” 
“We are delighted to bring this breakthrough, non-destructive treatment to millions of glaucoma sufferers,” said Jean-Marc Gendre, CEO of Quantel Medical. “The ability to lower IOP safely, with the added advantages of speed and ease for patients and surgeons alike, makes this a very exciting advance in treatment of glaucoma.” 

Celebrating the 3000th Compact Touch system

A major proof of the commercial success of our portable A/B system with the manufacturing of the 3000th Compact Touch unit.

Highly appreciated for the image quality in B mode and the measurement accuracy in biometry and pachymetry, Compact Touch is a worldwide commercial success since its launching in 2008.

Quantel Medical’s knowhow in ultrasound technology is recognized by opinion leaders worldwide and we are glad to see that Compact Touch highly contributes to our success.

Quantel Medical manufactures 3000th Vitra laser console

Quantel Medical is proud to announce the manufacturing of the 3000th Vitra laser console! This is a work of many hands and the achievement of a huge commercial success. This 3000th Vitra laser will soon leave our manufacturing plant to fly to the USA for installation. 

Quantel Medical Launches New Easyret Photocoagulator Laser

The fully integrated system brings ELBA fiber laser technology to macular and peripheral retinal procedures.

 

Quantel Medical (Quantel) announced the launch of the innovative new Easyret fully integrated 577nm yellow photocoagulator for macular and peripheral retinal pathologies.


“In 1995, Quantel was the first company to introduce solid-state diode-pumped technology for green photocoagulators. In 2016, Quantel is introducing a new revolution with fiber laser technology for 577nm yellow lasers. This technical breakthrough is based on Quantel’s proprietary ELBA fiber laser technology, which the company has utilized in scientific and industrial areas. We are very excited to bring this technology to ophthalmic surgeons and their patients,” said Jean‐Marc Gendre, CEO of Quantel Medical. “The Easyret’s ELBA fiber laser cavity delivers pure 577nm yellow wavelength in a uniform top-hat laser spot profile, making it ideal for ophthalmic applications. The technology is a compact, reliable variation on solid-state lasers that provides an extended lifetime of service. Quantel engineers worked closely with surgeons to design a fully integrated system with an intuitive interface to ensure optimal ergonomics and ease of use. Surgeons’ input was essential to the Easyret’s design, and we are pleased with their enthusiasm for this new technology.”


The Easyret has a broad range of settings for treatment of pathologies such as diabetic retinopathy, macular edema and central serous chorioretinopathy. In addition to SingleSpot treatment mode, surgeons can select Multispot mode for a pattern of simultaneous targets or the subthreshold Micropulse* mode, which enables them to customize a train of short pulses to precisely manage the thermal effect on targeted tissues.


*MicroPulse is a trademark of Iridex.

Quantel Medical Awarded Tender for Ophthalmic Laser Equipment from India Department of Defense

Agreement will place Quantel Medical SupraScan lasers in 53 military hospitals across India


Quantel Medical announced it has been awarded a €3 million competitive tender for ophthalmic laser equipment.

Under the terms of a supply agreement signed by the Directorate General of Armed Forces Medical Services of the Indian Ministry of Defense, Quantel Medical will provide 61 photocoagulator lasers (532nm Supra with Suprascan) for use in 53 military hospitals across India. The 532nm Supra with Suprascan is a diverse and versatile laser platform capable of delivering a number of Multispot and MicroPulse® patterns.


“Diabetes is extremely prevalent in India, affecting more than 62 million individuals, or about 7% of the adult population. It is well known that uncontrolled diabetes can be a precursor for the development of vision-related complications, including diabetic retinopathy and diabetic macular edema, both of which are also very common in India. One study suggested that as many as 20% of individuals with diabetes in India are affected by diabetic retinopathy,” said Jean‐Marc Gendre, CEO of Quantel Medical.


“This agreement will put an extremely powerful treatment option in the hands of physicians who treat patients with diabetic eye disease, and it is a platform that can be adapted to use for other applications as well. Laser treatment of diabetes is in many cases as effective as medical treatment, and it is demonstrated to be much more cost effective,” added Jean‐Marc Gendre, CEO of Quantel Medical.

Quantel Medical Launches New Website

Quantel Medical announces the launch of a fully redesigned website (www.quantel-medical.com). This new website provides comprehensive information about the company’s products and their associated clinical advantages. The new design and enhanced navigation incorporate a brand-specific color scheme to build cohesiveness with Quantel Medical messaging. Simplified site navigation and enhanced search capability make it quick and easy for the visitor to find the appropriate product or application information to suit a wide range of ophthalmic therapeutic solutions.

Other website features include:

  • Presentations, webinars, physicians’ testimonials, tutorials, case studies, clinical articles and guidelines about Quantel Medical products to provide added value for the ophthalmic community.
  • News and events, including a schedule of tradeshow participation across the globe, and information about Quantel Medical’s latest innovative products.
  • Convenient forms to request product pricing information, demos and brochures.
  • Easy access to Quantel Medical’s partners information worldwide
  • Integrated LinkedIn and YouTube buttons to nurture improved communication with clients while linking them to the partners’ portal (Extranet) for relevant internal information.

“With the redesign of our website, we hope to relaunch our commitment to providing cutting edge medical devices for the ophthalmic community. The new design reflects our intention to provide robust information for partners and media and be responsive to our customers’ needs while serving to provide even more information for end users, specifically, the eye care community. We believe that this new website will allow our visitors to have a very informative experience as we continue to grow and increase our market presence,” said Jean-Marc Gendre, CEO of Quantel Medical.

Quantel Medical Offers New Generation 10 MHz B Probe

Quantel Medical announces the availability of a new generation 10 MHz ultrasound B probe capable of never before available imaging of ocular anatomy, the vitreous, ocular wall, and vitreoretinal structures and features.

Several engineering advancements, including reduced signalCtoCnoise ratio, a large dynamic range, and high sensitivity, combine to offer unparalleled visualization and characterization capabilities for low reflective structures, such as inflammatory cells, blood cells, floaters, and membranes. Because it can produce superior image quality, the 10 MHz probe can facilitate the identification of critical ocular structures, including the posterior hyaloid, and aid in the differential diagnosis of anatomic changes at the vitreoretinal interface, such as tractional detachments and tears.

“Ultrasound is a safe, noninvasive diagnostic tool for the evaluation of a variety of ophthalmic disorders,” said Peter Good, MD, of the Birmingham and Midland Eye Center, United Kingdom. “The new B probe from Quantel Medical offers unparalleled image quality, excellent dynamic information, and new potential for tissue characterization and visualization. One small example of this is that the clinician will be better able to visualize blood flow to uveal tumors, thus adding to the ability to correctly diagnose this potentially serious ocular disorder.”

The 10 MHz probe is fully compatible with Quantel Medical’s Aviso and Aviso S platforms, Quantel Medical’s market leading ultrasound platforms that have been heralded for being multifunctional and versatile for use in various ophthalmic settings. Aviso and Aviso S are compatible with a full line of anterior and posterior segment probes to offer a full range of diagnostic capabilities. These platforms are powerful and adaptable diagnostic tools, offering full AC and BCscan capabilities for applications as diverse as ocular biometry to globe, orbit, retina, and anterior segment diagnostics.

Quantel Medical Launches Educational Website About 577 ­nm Wavelength MicroPulse® Laser Therapy

Quantel Medical announces the launch of a new website (www.retina-­yellow-­laser-­therapy.com) dedicated to educating the medical community about the benefits of using yellow wavelength light during ophthalmic surgeries. The website will serve as a resource for interested ophthalmic professionals to learn more about Quantel Medical’s proprietary 577-­‐nm MicroPulse® laser therapy, specifically about its applications in treating Diabetic Macular Edema (DME) and Central Serous Chorioretinopathy (CSCR).

 

Quantel Medical’s technology uses microsecond laser pulses, followed by intermittent cooling times, to deliver a thermal effect to the desired treatment area. Compared with continuous-­‐wave lasers, MicroPulse® requires less energy, and, therefore, engenders less of a risk of burns or scars. Yellow wavelength light, and in particular the 577 nm wavelength, has several desirable properties for retinal applications: it causes less scatter while requiring lower energy compared with green laser and other yellow light wavelengths; it is minimally absorbed by xanthophylls, potentially allowing for treatment near the fovea; because it is highly absorbed by oxyhemoglobin, it is ideal for treating vascular lesions and subretinal vascular proliferations; and the 577-­‐nm wavelength is capable of penetrating opacified media, such as cataracts.

 

“Our goal in launching this website is to provide an educational resource about Quantel Medical’s laser therapy that will help the medical community better understand the strong rationale and definite clinical benefits 577-­‐nm wavelength laser therapy provides in the treatment of retinal disorders,” said Jean-­‐Marc Gendre, CEO of Quantel Medical. MicroPulse® offers a viable and potentially safer alternative to continuous-­‐wave laser therapy, and, when combined with use of 577-­‐nm wavelength light, offers physicians a versatile, safe and effective clinical tool for treating retinal disorders. It also offers an interesting adjunct or alternative to anti VEGF therapies.”

 

The website will serve as a clearinghouse of studies, presentations, and other published literature pertaining to the safety and efficacy of 577 nm MicroPulse® therapy for various ophthalmic applications. Also on the site are videos from prominent surgeons Victor Chong, MD; Sacha Fauser, MD; Giovani Staurenghi, MD; and Emin Ozmert, MD, which were recorded at a sponsored symposium held by Quantel Medical at a recent congress.

 

Although much recent research in the treatment of DME has centered on medical management, laser therapy has long been considered an important management strategy. Additionally, laser therapy remains the only proven option for DME that does not involve the fovea. Clinical studies demonstrate that MicroPulse® using 577-­‐ nm wavelength light effectively reduces edema, with effects lasting for 6 months or longer. The effects may not be as apparent as quickly as with medical therapy, however, they tend to last longer and cost less than treatment with anti-­‐VEGF therapy.

 

In the treatment of CSCR, 577-­‐nm MicroPulse® offers an alternative to thermal photocoagulation for extrafoveal leakages without causing symptomatic scotomas and choroidal neovascularization. In a recently completed retrospective study, subthreshold Micropulse® laser treatment in patients with CSCR lowered central retinal thickness by a mean 115 µm and improved visual acuity by a mean 0.06 logMAR after a mean of 5 months of follow up. There were no laser burns detected among the 38 patients.

 

The 577-­‐nm MicroPulse® laser therapy is available on Quantel Medical’s Supra Scan 577 treatment platform. It offers a wide range of pattern scans and customizable retina patterns, as well as the proprietary MicroPulse® Mode, to provide a powerful tool for the treatment of many retinal disorders.

Quantel Medical's Vitra™ PDT Laser receives CE Mark approval

Quantel Medical today announced CE Mark approval for its Vitra™ PDT photodynamic therapy laser platform, for the treatment of polypoidal choroidal
vasculopathy (PCV) and central serous retinopathy (CSR). Quantel, the sole manufacturer of this laser technology, plans to begin commercializing the laser platform immediately in countries requiring CE registration.

PCV, a disease of the choroidal vasculature, is present in both men and woman of many ethnicities, characterized by detachments of the pigmented epithelium and exudative changes that can commonly lead to subretinal fibrosis. It is reported to be prevalent in 20% to 50% of Asian patients with presumed
neovascular age-related macular degeneration (AMD) and in 4% to 12% of caucasians. However, it is currently believed that the true prevalence of disease is underreported, and accordingly, additional demand for treatment modalities is anticipated. Studies have demonstrated excellent short-term efficacy of PDT for treating PCV.

CSR, also known as central serous chorioretinopathy (CSC), is an eye disease which causes visual impairment, often temporary, usually in one eye. When the disorder is active, it is characterized by leakage of fluid under the retina that has a propensity to accumulate under the central macula.

“Quantel is currently the sole provider of a laser approved to treat these two very serious retinal conditions,” commented Jean-Marc Gendre, Chief Executive Officer of Quantel Medical. “This comes at an opportune moment, as demand for PDT treatment technologies is expected to increase as the disease’s true prevalence is realized. We’re confident that our world-class laser technology will provide ophthalmologists a quality, cost-effective solution, and are excited to begin commercialization in Europe and Asia. This product development, supported by Novartis, Basel, Switzerland, will propose an updated solution for current and future PDT users.”

Quantel Medical announces addition of two new disposable products to portfolio

Quantel Medical announced the introduction of two new disposable product ranges. The latest additions to their portfolio will be showcased at the annual congresses of the European Cataract and Refractive Surgeons (ESCRS) and the American Academy of Ophthalmology (AAO).

The launches include Vitra™ Probes, a next-generation range of laser probes, compatible with Quantel Supra and Vitra™ laser systems. The laser probes are used in conjunction with photocoagulation lasers for the treatment of retinal diseases. The extended range features two new, unique designs, including a flexible tip laser probe and a steerable laser probe.

The new steerable probe allows unparalleled access to the retina with its steerable concept and 360° rotatable handle. The flexible curved probe's exclusive design features a flexible needle with a memory shape effect. Each probe in the line offers operator comfort of use with its optimized features.
The introduction of Quantel's new, single use diagnostic and treatment lenses brings improved optical quality and safety, not previously available in the market. The new, advanced design of the single use lenses feature larger, flatter mirrors resulting in a wider, improved field of view. In addition to the
optical improvement, the lenses provide a solution to many of the concerns that are often associated the risk of infection from improper disinfection of traditional, reusable lenses.

The single use lenses, packaged in a sterile pouch and discarded after one-time use, offer infection control compliance, and eliminate costly, time-consuming disinfection and sterilization processes. Studies have shown that hundreds of eye infections are linked to ophthalmology clinics, validating that eye care facilities need strict adherence to infection control measures.

While aging reusable lenses may compromise image quality and limit therapeutic treatment, Quantel single use lenses provide a pristine view for diagnosis and treatment, and ideal laser transmission every time.

"The two new product introductions reflect Quantel's commitment to bring innovative new technologies to market that address the needs of our customers and their patients,” commented Jean-Marc Gendre, Chief Executive Officer of Quantel Medical. “We are excited to bring these new product breakthroughs to the eye care community on a global level.

Quantel Medical’s Optimis Fusion™ receives FDA 510(k) Clearence

Quantel Medical today announced FDA 510(k) clearance for its Optimis Fusion™ integrated laser platform. The Optimis Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to  offer  ophthalmologists  a  versatile  armamentarium  for  treating  both  cataract  and  glaucoma  in  an efficient combination platform.

The Fusion’s unique SLT mode incorporates the most advanced laser technology available to provide a first-­‐choice treatment for managing glaucoma and lowering intraocular pressure. SLT therapy works by targeting  melanin-­‐rich  cells  that  absorb  the  laser  energy  to  induce  a  healing  response,  improving  the function  of  the  trabecular  meshwork.  Laser  energy  is  delivered  in  short,  fixed  pulses  over  a  large, homogeneous  spot  size,  resulting  in  no  thermal  damage.  Due  to  this  gentle  delivery  and  lack  of permanent destruction to the trabecular meshwork, SLT leaves structures intact, making it a repeatable procedure.

The  YAG  mode  delivers  high-­‐performance  photodisruption  for  capsulotomy  and  peripheral  iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels,  avoiding  adverse  side  effects  such  as  lens  pitting.  Precise  tissue  targeting  is  achieved  with  the advanced  two-­‐point  aiming  beam,  allowing  for  fast  and  accurate  targeting  of  the  capsule,  and  an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

“We are extremely excited to bring our breakthrough laser platform to the U.S. market,” said Jean-­‐Marc Gendre, CEO of Quantel Medical. “The Optimis Fusion has proven to be a very attractive laser platform since introduction earlier this year in other markets. Driving the acceptance of this product introduction is  the  ability  to  combine  a  532nm  mono  spot  or  multispot  retina  laser,  a  unique  feature  to  Quantel’s laser line. “

Integrating the  Optimis  Fusion  with  Quantel’s Vitra™  Monospot and  Multispot pattern-­‐scanning  retina laser  systems,  offers  comprehensive  treatment  options  for  multi-­‐specialty  practices  looking  to  treat glaucoma, cataract and retina conditions in one laser platform.
 

About Glaucoma
Glaucoma  is  a  group  of  diseases  that  damage  the  eye’s  optic  nerve  and  can  result  in  vision  loss  and blindness. Glaucoma can be roughly divided into two main categories, "open-­‐angle" and "closed-­‐angle" (or "angle closure") glaucoma.

About Cataract
A cataract is a clouding of the lens inside the eye, which leads to a decrease in vision. It is the most common cause of blindness and is conventionally treated with surgery.

Quantel Medical establishes International Laser Advisory Board

Quantel Medical today announced a treatment guideline for the use of subthreshold MicroPulse® laser for treating diabetic macular edema using Quantel’s SupraScan™ 577 laser platform. The introduction of the treatment guideline is the first step to initiating a multi-center study design in which all participating sites can perform the laser treatment under the same parameters. The study design will have two main objectives; one, to achieve improved patient care for DME patients in the era of anti-VEGF treatments, and two, establish the indications for use and the optimum subthreshold MicroPulse® laser treatment parameters to be used.

Quantel Medical’s Advisory Board Chairman, Professor Victor Chong, MD, FRCS, FRCOphth, Oxford Eye Hospital, initiated the creation of the treatment guidelines working with the SupraScan 577. Professor Chong presented the initial results of a histological study at ARVO in May 2014. The histological animal study was a key milestone in establishing the criteria for the treatment guidelines, including clinical validation of the preferred wavelength to use, the recommended duty cycle to use, and the optimum “dosage” of energy for MicroPulse® delivery. This study confirmed the clinical findings that retina was best preserved by using MicroPulse® subthreshold laser photocoagulation with the 577nm wavelength, a 5% duty cycle and by reducing power to 50% of threshold power.

Quantel Medical’s establishment of their international laser advisory board and the introduction of a formal treatment guideline demonstrate a significant step in supporting their ophthalmologist customers in improving patient care. Jean-Marc Gendre, CEO of Quantel Medical, commented: “Our long-term goal is to establish the ongoing importance and role of laser in the treatment of retina diseases. With a common protocol, we can now develop the clinical studies necessary to produce the data for this goal. Working with our KOL’s we are confident that we can support their management of their DME patients.”

Quantel Medical’s SupraScan 577 laser is the ideal platform to be used in this study due to its 577nm yellow wavelength, offering ideal energy absorption, and its multispot delivery mode, offering uniform placement and homogeneous laser impacts across the intended targets. These two advanced features combined with MicroPulse® delivery mode provide the most advanced laser platform for treating retina diseases.

Quantel Medical’s Optimis Fusion™ receives CE mark

Quantel Medical announced CE Mark approval for its Optimis Fusion™ integrated laser platform. The Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma. Quantel will immediately begin commercialization in all CE Mark-approved countries. FDA approval is expected in 2014.

The Fusion’s unique SLT mode incorporates the most advanced laser technology available to provide a first-choice treatment for managing glaucoma and lowering intraocular pressure. SLT therapy targets melanin-rich cells, which absorb the laser energy to induce a healing response that begins to improve the function of the trabecular meshwork. The laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. Due to the gentle delivery and no permanent destruction to the trabecular meshwork, SLT leaves the structures intact and can be repeated if necessary.

The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

“This approval constitutes a critical milestone for our medical laser business,” said Jean-Marc Gendre, CEO of Quantel Medical. “We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design. Through our engineering expertise, we continue to provide the most advanced laser solutions to the market.”

In addition to this world-class SLT and YAG combination laser, the Fusion integrates smoothly with Quantel’s Vitra™ Monospot and Multispot pattern-scanning retina laser systems, offering comprehensive treatment options for multi-specialty practices to treat glaucoma, cataract and retina conditions in one laser platform.

Quantel Medical’s Solutis granted FDA clearance

Quantel Medical, a world leader in ophthalmic ultrasound and laser devices, today announced that Solutis™, an SLT (selective laser trabeculoplasty) glaucoma laser, has been approved for clinical use by the U.S. Food and Drug Administration.

Quantel Medical sells 400th Multispot Laser

Quantel Medical, a world leader in ophthalmic ultrasound and laser devices, today announced that it recently sold its 400th Multispot laser for the treatment of retinal disease, including, among others, diabetic macular edema (DME), central serous retinopathy and retinal vein occlusion (RVO). Quantel’s two Multispot laser systems – the SupraScan™ 577 and Vitra Multispot™ – offer a comprehensive range of treatment patterns in conjunction with precisely controlled laser emission, providing an improved experience for both patient and physician.

Both Multispot lasers leverage pattern-scanning technology to achieve optimal treatment results. Short, 10-20ms pulses are placed in a variety of potential patterns, resulting in reduced heat diffusion to the retina and choroid and, subsequently, reduced collateral damage to surrounding tissue. Multispot treatment is characterized by a more comfortable experience for patients, extremely efficient treatment (full pan-retinal photocoagulation (PRP) is possible in 2 sessions), and shorter laser sessions, when compared to traditional laser treatment.

“The sale of our 400th Multispot laser constitutes a critical milestone for Quantel,” noted Mr. Jean-Marc Gendre, CEO of Quantel Medical. “Quantel’s pattern-scanning laser technologies provide retinal specialists and comprehensive ophthalmologists the highest-quality technology to achieve optimum treatment results. As we continue to innovate, we will bring additional bestin- class technologies to ophthalmologists across the world.”

The SupraScan 577 is a 577nm photocoagulation laser that adapts to Haag Streit-type slit lamps. 577nm wavelength treatment is both efficient and efficacious, utilizing less power during treatment and achieving excellent combined absorption by both melanin and oxyhemoglobin, making 577nm an ideal choice for penetrating cataracts and hazy media. Additionally, the system is capable of performing MicroPulse™*, a tissue-sparing treatment mode that segments laser delivery into a sequence of extremely short, microsecond pulses.

The Vitra Multispot is a 532nm portable multispot laser that also adapts to Haag Streit-type slit lamps. The system utilizes electronically controlled laser emissions based on the “Start and Stop” principle: unlike other lasers, the system does not use galvo mirrors to control pulse duration, resulting in a laser beam always perfectly centered in the fiber and laser pulses generated and controlled by the laser itself. Subsequently, this technology ensures excellent
spot-to-spot laser burn consistency, and that fluence is controlled and consistent for each spot.

Quantel Medical announce the introduction of two new diagnostic ultrasound probes

Quantel Medical announce the introduction of two new diagnostic ultrasound probes to their flagship ultrasound platforms, Aviso™ and Aviso S™ at the American Society of Cataract and Refractive Surgery annual meeting:

  • New 50 MHz UBM probe
  • New 10 MHz B-scan probe 

Quantel Medical Receives FDA Clearance for new Vitra Multispot Laser System

Quantel Medical today announced the U.S. Food and Drug Administration (FDA) 510(k) market clearance of the Vitra Multispot™ laser.

The product was developed by Quantel Medical to give access to advanced pattern-scanning technology to ophthalmology practices worldwide though intelligent design.

Quantel Medical Receives FDA Clearance for new SupraScan 577 Laser System

Quantel Medical has announced U.S. Food and Drug Administration (FDA) 510(k) market clearance of its SupraScan 577 Laser, an ophthalmic laser system for treating a wide range of retinal diseases. The SupraScan 577 uniquely combines three of the most clinically sought-after components in a retina laser – 577nm yellow wavelength, pattern-scanning, and MicroPulse® tissue-sparing laser emission modes.

Mr. Jean-Marc Gendre, CEO of Quantel Medical, commented, "We are proud to have passed this regulatory milestone. Quantel was the first company in the world to bring to market a solid-state green retina laser in 1993, followed by a solid-state yellow retina laser in 2008.. Today’s announcement of 510(k) clearance for the SupraScan 577, the most advanced solidstate yellow scanning retina laser allows Quantel USA to offer a market-changing solution to retina specialists in the U.S.”

The clinical absorption characteristics of the 577nm yellow wavelength, specifically high absorption in oxyhemoglobin and low absorption in xanthophyll pigments, coupled with the ability to efficiently transmit through opaque ocular media have made it the wavelength of choice for retina treatments. Quantel’s SupraScan 577 is the first yellow laser on the market capable of pattern scanning delivery in both conventional and tissue-sparing MicroPulse® modes available in the U.S.

About MicroPulse® Technology
MicroPulse® is a Fovea-friendly tissue-sparing laser delivery therapy that works by electronically “chopping” the laser emission into trains of microsecond pulses. This enhances the physician’s ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

Quantel Medical Signs Global Licensing Agreement with Iridex

Quantel Medical today announced that Iridex and Quantel Medical have signed a global patent licensing agreement that gives Quantel
access to Iridex MicroPulse® technology. This proprietary technology provides ophthalmologists a noninvasive treatment for sight-threatening diseases of the eye, including complications associated with diabetes. Unlike conventional laser therapy, MicroPulse® spares the eye tissue responsible for vision while producing comparable clinical effect to traditional methods that destroy tissue.

“There is a significant need in the market place for efficient and durable therapies for retinal diseases associated with the growth of diabetes and the aging population,” stated Will Moore, Iridex President and CEO. He continued, “With 10-year follow up data, a growing global user base, and significant patent protection, MicroPulse® is emerging as a future standard of care.” The license agreement will allow Quantel Medical to market and display Iridex’ MicroPulse® technology for their range of high quality clinical lasers and is the next step in gaining broad market availability of MicroPulse® photocoagulation lasers. Both Quantel Medical and Iridex offer a full line of laser systems that offer standard photocoagulation in addition to MicroPulse® laser therapy.

Moore continued, “Further establishing the MicroPulse® brand and technology as an Iridex property is critical as the market continues to recognize its broad applicability for retina and other procedures. We look forward to working with others in the industry as it migrates toward a new standard for laser therapy in additional segments.”

“The global clinical evidence supporting Iridex’ MicroPulse® laser technology was an important factor in this decision”, stated Mr. Jean-Marc Gendre, CEO of Quantel Medical. He continued, “By aligning our market strategies with another industry leader, we believe the ophthalmic community will have greater access to MicroPulse® technology, helping to improve the standard of care for retinal diseases. We also believe that this collaboration will be the most
efficient method to standardize MicroPulse® clinical protocols for our customers.”

About MicroPulse® Technology
MicroPulse® is a Fovea-friendly tissue-sparing laser delivery therapy that works by electronically “chopping” the laser emission into trains of microsecond pulses. This enhances the physician’s ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

 

Quantel announces the sale of its Dermatology-Aesthetics Lasers business

In July 2012, Quantel signed an agreement with the Israeli firm ALMA Lasers to sell its Dermatology-Aesthetics Lasers business. Quantel Derma is now Alma Lasers.

QUANTEL will continue to produce the devices from the dermatology range on behalf of ALMA. This manufacturing agreement is being entered into for a minimum of one year and may be renewed if requested by ALMA.

This sale will also pave the way for the Medical Division to focus on developing the Ophthalmology business, which is continuing to increase its market shares thanks to the innovative products released during the last few years.

Learn more about:     

Quantel Medical set to make its mark on the US

Ophthalmology solutions expert, Quantel Medical, has announced the expansion of its US operation.

“In recent years, Quantel Medical has established a strong track record for bringing innovative technology to the international eyecare market. We see the expansion of our operation in the US as an exciting next chapter in the Quantel Medical story,” said Peter Falzon, the newly-appointed General Manager of Quantel USA Inc, Medical Division.

“Quantel’s ophthalmology business has been growing in excess of 20% per year for each of the past three years driven by new product introductions and good customer service. Our strategy to invest more in the US market will result in more sales, marketing, training and technical resources in the field to support our customers” said Mr. Falzon.

Strong Track Record for Innovation
Founded in 1993 in Clermont-Ferrand, France, Quantel Medical is a world leader in the development of innovative ophthalmology solutions. The company’s wide range of ultrasound and laser devices provides diagnostic and therapeutic solutions tailored to the specific needs of patients and doctors.

Quantel Medical continues to develop and update its innovative product range -- Recent additions to the product line include the Aviso – a comprehensive ultrasound platform offering seven probes, including the 50MHz UBM, and the Supra Scan – the only photocoagulator platform to offer both pattern scanning and micropulse technology.

Quantel Medical now hopes to use its US organization in Bozeman, Montana, to increase brand recognition within the US eyecare industry and to facilitate product integration and innovation in the US market as a whole.

“Quantel is uniquely positioned in today’s ophthalmology market for three reasons: Our well recognized and reputable name in ophthalmology, our presence in 85 countries around the world, and our capacity to quickly develop and commercialize innovative products,” said Quantel Medical CEO, Jean-Marc Gendre. “We are looking forward to establishing a wider customer base in the US.”

Opening ceremony of the new Quantel Medical headquarters

Tuesday November 8, 2011, Quantel Medical inaugurated its new premises.

Career

Your application